Patent problems

The Supreme Court has finally ended Novartis' seven-year quest to patent its cancer drug Glivec in India. In 2006, after the Patent Controller in Chennai rejected the patent, Novartis went to court against the Government of India, a patients' lobby, and four Indian companies that manufacture generic drugs (Natco, Cipla, Hetero and Ranbaxy), before the Madras High Court.

Read Full Story>>